Diabetes is one of the world’s major metabolic diseases, involving defects in insulin secretion and/or insulin resistance. We provide research-grade antibodies and small-molecule tools to study mechanisms, complications, and therapeutic strategies.
Focus areas: insulin signaling, hepatic gluconeogenesis, immuno-metabolism, β-cell stress
Commonly used for mechanistic studies; follow your lab SOP, compound datasheets, and ethics approvals.
| Compound | Targets / pathways | Experimental notes |
|---|---|---|
| LY294002 | PI3K (upstream of PI3K–AKT) | Common for insulin signaling branch validation; mind cytotoxicity/off-targets—use dose/time matrices. |
| MK-2206 | AKT1/2/3 | Useful for AKT-dependent metabolic phenotypes; watch feedback loops (RTK/MAPK) confounding interpretation. |
| Rapamycin | mTORC1 (FKBP12–Raptor) | Classic autophagy/synthetic metabolism tool; prolonged treatment may engage mTORC2 feedback—pair controls. |
| AICAR | AMPK-activating tool compound | Common for energy-stress reprogramming studies; support with phospho-readouts and upstream kinase controls. |
| Metformin | Mitochondrial complex I / AMPK axis (model-dependent) | Often used as a chronic positive control; in vitro dose windows vary strongly by cell type. |
| Ruxolitinib | JAK1/2 | Useful for cytokine/immune-metabolism crosstalk; mind immunosuppression in in vivo IR models. |
| MG132 | Proteasome | For proteostasis/degradation dependency; high cytotoxicity—tightly window doses. |